ロード中...
Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia
CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy is effective in refractory/relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL). This review focuses on achievements, current obstacles, and future directions in CAR-T research. A high complete remission rate of 68% to 93% could be...
保存先:
| 出版年: | Chin Med J (Engl) |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Health
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7046249/ https://ncbi.nlm.nih.gov/pubmed/31977556 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000000638 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|